{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T14:50:29Z","timestamp":1766760629435,"version":"3.41.2"},"reference-count":10,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,1,18]]},"abstract":"<jats:p>Telavancin, a lipoglycopeptide antibiotic, is traditionally dosed at 10\u2009mg\/kg based on total body weight but is associated with toxicities that limit its use. This study supports the use of a capped dosing regimen of 750\u2009mg in obese patients, which is associated with equal efficacy and fewer adverse effects compared to traditional dosing.<\/jats:p>","DOI":"10.1128\/aac.01603-21","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T21:53:47Z","timestamp":1634594027000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of a Capped Dosing Telavancin Regimen Compared to Standard Dosing at a Large Community Teaching Hospital"],"prefix":"10.1128","volume":"66","author":[{"given":"Fernando J.","family":"Diggs","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Huntsville Hospital, Huntsville, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan D.","family":"Edwards","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Huntsville Hospital, Huntsville, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly B.","family":"Garza","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes Research and Policy, Auburn University Harrison School of Pharmacy, Auburn, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali A. M.","family":"Hassoun","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Huntsville Hospital, Huntsville, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6448-3879","authenticated-orcid":true,"given":"Spencer H.","family":"Durham","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Auburn University Harrison School of Pharmacy, Auburn, Alabama, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G417"},{"key":"e_1_3_2_3_2","unstructured":"Cumberland Pharmaceuticals Inc. July 2020. Vibativ package insert. Cumberland Pharmaceuticals Inc. Nashville TN."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/587896"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq031"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr518"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0505-8"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/11534440-000000000-00000"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05915-11"},{"key":"e_1_3_2_10_2","unstructured":"Jenkins B Reyes SD Lanza E Reilly J Trivedi M. 2017. Clinical and financial evaluation of a 750 mg ceiling-dose telavancin regimen in obese patients poster 8-069. Presented at the 51st ASHP Midyear Clinical Meeting and Exhibition. December 2016 Las Vegas NV."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02475-17"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01603-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01603-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:40:33Z","timestamp":1645486833000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01603-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,18]]}},"alternative-id":["10.1128\/AAC.01603-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.01603-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"type":"print","value":"0066-4804"},{"type":"electronic","value":"1098-6596"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"assertion":[{"value":"2021-08-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01603-21"}}